# OnCo record nct04592653 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04592653/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04592653", "NCT04592653" ;
  schema:name "Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)"@en ;
  schema:alternateName "ARTISTRY-3"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Mural Oncology, Inc, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04592653/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04592653> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2020-09-30" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> .